Growing Market Reach PepGen is actively expanding its clinical pipeline and increasing funding through public offerings, indicating a strong commitment to advancing innovative therapies which presents opportunities to provide supporting infrastructure, analytics, or partnership solutions to aid their growth trajectory.

Focus on Rare Diseases With recent presentations at the International Congress of the World Muscle Society and a focus on neuromuscular disorders, PepGen targets a niche market with high unmet medical needs, creating potential for sales of specialized diagnostics, research tools, or patient management solutions.

Financial Expansion Having secured substantial funding of $158M and executing multiple equity raises, PepGen is in a position to invest heavily in innovative R&D and technology platforms, offering opportunities for advanced biotech tools, data management solutions, and research collaborations.

Partnership & Collaboration PepGen's focus on developing next-generation oligonucleotide therapies provides potential sales avenues with contract research organizations, biotech collaborators, and equipment suppliers that support gene therapy development and clinical trial execution.

Innovation Leadership PepGen's proprietary EDO platform and recent clinical milestones demonstrate leadership in oligonucleotide technology, creating opportunities to sell cutting-edge delivery systems, analytical services, and integration tools to enhance their therapeutic development efforts.